China is investigating pharmaceutical prices

07/7/2013 | PharmaTimes (U.K.)

China's National Development and Reform Commission has launched an investigation of costs and pricing at as many as 60 drug manufacturers, including GlaxoSmithKline, Merck, Astellas, Boehringer Ingelheim, Novartis' generics unit and possibly two Chinese-owned firms. Investigators will visit the companies between this month and October, according to reports. Ben Cavender of the China Market Research Group speculated that, because trust in domestic drug companies is so low, consumers are willing "to spend extra to buy foreign products," triggering concerns about price levels and safety.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN